Benchmarking: GENE ONE
Benchmarking: Gene One
Benchmarking Analysis: Gene One
Gene One is a biotech industry that has created a unique gene technology that has helped farmers no longer require the need for pesticides for their tomato or potato crops. With this technology, consumers do not need to concern themselves with chemicals that have harmed their vegetables in the past. This gene technology helped Gene One go from a $2 million dollar company to a $400 million company in just 8 years. Wall Street is showing rising stock and growing interest in biotechnology along with leadership changes at the FDA to push investors towards the biotech industry. Gene One believes they will need to go public within the next 3 years in order to keep up with the demand and meet their target growth of 40%. Gene One will use the money raised to acquire capital, develop new products, and increase their advertisement and marketing. Don Ruiz, CEO of Gene One, presented his strategy to the Board and received their approval; with the go-ahead from the Board, Don is now in the position to implement his plan with the help of his Senior Leadership Team. Through our research, our team has discovered several companies that have experienced similar circumstances as that of Gene One. These companies started small and have grown tremendously over a few years. With the market being as competitive as it is today, these companies need to raise money to develop newer products, advance their technologies, and seek growth for their businesses with the help of IPO’s. Throughout this paper, our team will discuss the different companies we have researched and the different reasons why they have decided to go public.
Individual Company Synopses
Orbitz Inc. is one of the leading online travel industries available to consumers and businesses today. Orbitz offers low fares for airlines, hotels, car rentals, cruises, and a vast array of vacation packages. Orbitz...